,Gene,Gene synonym,Ensembl,Gene description,Chromosome,Position,Protein class,Evidence,Antibody,Reliability (IH),Reliability (Mouse Brain),Reliability (IF),Subcellular location,Prognostic p-value,RNA cancer category,RNA tissue category,RNA TS,RNA TS TPM,TPM max in non-specific,RNA cell line category,RNA CS,RNA CS TPM
0,NKX2-5,"CSX, CSX1, NKX2.5, NKX2E, NKX4-1",ENSG00000183072,NK2 homeobox 5,5,173232109-173235357,"Disease related genes, Predicted intracellular proteins, Transcription factors",Evidence at protein level,HPA065034,,,Approved,Nucleoplasm<br>Cytosol,,Mixed,Group enriched,126,heart muscle: 32.7;spleen: 14.5,"breast,placenta,urinary bladder: 0.1",Cell line enhanced,,HEK93: 27.1;NTERA-2: 10.7;U-2 OS: 24.8;U-251 MG: 15.4
1,NMRK2,"ITGB1BP3, MIBP, NRK2",ENSG00000077009,Nicotinamide riboside kinase 2,19,3933103-3942416,"Enzymes, Predicted intracellular proteins",Evidence at protein level,"HPA049909, HPA054792, HPA072450",Approved,,Enhanced,Nucleoplasm<br>Vesicles,Renal cancer:1.19e-4 (favourable),Tissue enhanced,Group enriched,49,heart muscle: 374.4;skeletal muscle: 218.4,esophagus: 6.1,Group enriched,9.0,BEWO: 28.1;NTERA-2: 24.3
2,HRC,MGC133236,ENSG00000130528,Histidine rich calcium binding protein,19,49151198-49155424,"Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,HPA004833,Enhanced,,,,,Mixed,Group enriched,39,heart muscle: 351.8;skeletal muscle: 155.5,"epididymis,prostate: 6.5",Group enriched,6.0,Hep G2: 3.9;HSkMC: 4.0;K-562: 7.1;THP-1: 9.3;U-266/84: 3.0
3,FBXO40,"Fbx40, KIAA1195",ENSG00000163833,F-box protein 40,3,121593119-121630295,"Plasma proteins, Predicted intracellular proteins",Evidence at protein level,,,,,,,Not detected,Group enriched,36,heart muscle: 56.2;skeletal muscle: 54.0,prostate: 1.5,Not detected,,
4,MYL2,CMH10,ENSG00000111245,Myosin light chain 2,12,110910819-110920722,"Candidate cardiovascular disease genes, Disease related genes, Predicted intracellular proteins",Evidence at protein level,"HPA019763, HPA039262",Supported,,Uncertain,Microtubules,Head and neck cancer:2.60e-4 (unfavourable),Group enriched,Group enriched,36,heart muscle: 16309.5;skeletal muscle: 9731.7,esophagus: 357.2,Group enriched,6.0,EFO-21: 3.7;HSkMC: 6.1;U-2 OS: 17.9
5,C10orf71,FLJ45913,ENSG00000177354,Chromosome 10 open reading frame 71,10,49299193-49327487,Predicted intracellular proteins,Evidence at protein level,,,,,,,Tissue enhanced,Group enriched,34,heart muscle: 28.8;parathyroid gland: 74.8;skeletal muscle: 97.7,prostate: 1.9,Group enriched,17.0,K-562: 6.2;RH-30: 9.6
6,ACTN2,,ENSG00000077522,Actinin alpha 2,1,236686454-236764631,"Disease related genes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Transporters",Evidence at protein level,"HPA006035, HPA008315",Enhanced,,,,,Tissue enhanced,Group enriched,28,heart muscle: 477.5;skeletal muscle: 758.7,esophagus: 22.4,Cell line enhanced,,HEK93: 1.8;HSkMC: 5.5;hTEC/SVTERT24-B: 4.9
7,MYH7,"CMD1S, CMH1, MPD1",ENSG00000092054,Myosin heavy chain 7,14,23412738-23435718,"Candidate cardiovascular disease genes, Disease related genes, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,"HPA001239, HPA001349, CAB015384",Enhanced,,,,,Group enriched,Group enriched,27,heart muscle: 2309.1;skeletal muscle: 5111.1,esophagus: 135.7,Cell line enriched,23.0,HSkMC: 8.2
8,MYPN,MYOP,ENSG00000138347,Myopalladin,10,68106117-68212017,"Disease related genes, Predicted intracellular proteins",Evidence at protein level,"HPA036299, HPA061494",Enhanced,,Approved,Nucleus<br>Vesicles<br>Cytosol,,Tissue enriched,Group enriched,27,heart muscle: 41.6;skeletal muscle: 99.9,prostate: 2.6,Cell line enhanced,,BJ: 33.6;fHDF/TERT166: 87.0;HBF TERT88: 24.6;LHCN-M2: 39.6
9,LRRC14B,,ENSG00000185028,Leucine rich repeat containing 14B,5,191511-195353,Predicted intracellular proteins,Evidence at protein level,"HPA038046, HPA038047",Uncertain,,,,,Tissue enhanced,Group enriched,26,heart muscle: 13.6;skeletal muscle: 30.1,prostate: 0.8,Cell line enhanced,,REH: 6.8;U-266/70: 7.1;U-266/84: 28.6
10,CSRP3,"CLP, CMD1M, MLP",ENSG00000129170,Cysteine and glycine rich protein 3,11,19182030-19210573,"Disease related genes, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,HPA042581,Enhanced,,,,,Tissue enriched,Group enriched,25,heart muscle: 1501.4;skeletal muscle: 467.9,prostate: 40.1,Not detected,,
11,KCNJ4,"HIR, hIRK2, HRK1, IRK3, Kir2.3",ENSG00000168135,Potassium voltage-gated channel subfamily J member 4,22,38426327-38455199,"Predicted membrane proteins, Voltage-gated ion channels",Evidence at protein level,,,,,,,Tissue enhanced,Group enriched,25,cerebral cortex: 40.9;heart muscle: 11.4,gallbladder: 1.0,Cell line enriched,8.0,SCLC-21H: 13.4
12,COX6A2,,ENSG00000156885,Cytochrome c oxidase subunit 6A2,16,31427731-31428428,"Predicted intracellular proteins, Transporters",Evidence at protein level,,,,,,,Group enriched,Group enriched,23,heart muscle: 687.3;skeletal muscle: 1846.8,esophagus: 54.9,Cell line enhanced,,HSkMC: 1.6;SiHa: 1.0;U-266/84: 7.0
13,CKMT2,SMTCK,ENSG00000131730,"Creatine kinase, mitochondrial 2",5,81233285-81266397,"Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,HPA051880,Enhanced,,,,,Mixed,Group enriched,22,heart muscle: 710.7;skeletal muscle: 505.3,adrenal gland: 27.9,Cell line enhanced,,BEWO: 3.3;T-47d: 5.1
14,SMPX,"DFN6, DFNX4",ENSG00000091482,"Small muscle protein, X-linked",X,21705972-21758163,"Disease related genes, Predicted intracellular proteins",Evidence at protein level,HPA077360,,,Approved,Plasma membrane,Head and neck cancer:3.04e-5 (unfavourable),Tissue enhanced,Group enriched,22,heart muscle: 456.2;skeletal muscle: 383.1,esophagus: 19.4,Cell line enhanced,,CACO-2: 1.2;Hep G2: 2.7;HSkMC: 3.0;Karpas-707: 2.2;U-266/70: 3.3;U-266/84: 1.2
15,XIRP2,CMYA3,ENSG00000163092,Xin actin binding repeat containing 2,2,166888487-167259753,"Cancer-related genes, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,"HPA034813, HPA074599",Uncertain,,Approved,Nucleoplasm<br>Plasma membrane,,Tissue enriched,Group enriched,22,heart muscle: 84.0;skeletal muscle: 301.6,prostate: 8.8,Cell line enhanced,,AN3-CA: 1.4;HUVEC TERT2: 3.5;U-2197: 2.7
16,FSD2,"RP11-127F21, SPRYD1",ENSG00000186628,Fibronectin type III and SPRY domain containing 2,15,82755362-82806070,Predicted intracellular proteins,Evidence at protein level,,,,,,,Not detected,Group enriched,21,heart muscle: 34.5;skeletal muscle: 53.5,esophagus: 2.1,Mixed,,
17,TRDN,,ENSG00000186439,Triadin,6,123216339-123637093,"Disease related genes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters",Evidence at protein level,"HPA038226, HPA058226",Enhanced,,Approved,Plasma membrane<br>Cytosol,,Tissue enhanced,Group enriched,21,heart muscle: 273.5;skeletal muscle: 650.2,prostate: 22.2,Cell line enhanced,,MCF7: 1.4
18,UNC45B,"CMYA4, UNC45",ENSG00000141161,Unc-45 myosin chaperone B,17,35147817-35189345,"Disease related genes, Predicted intracellular proteins",Evidence at protein level,HPA017861,Uncertain,,Supported,Cytosol,,Group enriched,Group enriched,21,heart muscle: 65.8;skeletal muscle: 68.0,prostate: 3.1,Group enriched,9.0,BEWO: 1.6;HSkMC: 1.8
19,C14orf180,"C14orf77, NRAC",ENSG00000184601,Chromosome 14 open reading frame 180,14,104579684-104590515,"Predicted intracellular proteins, Predicted membrane proteins",Evidence at transcript level,,,,,,,Tissue enhanced,Group enriched,19,adipose tissue: 34.5;heart muscle: 28.5,adrenal gland: 1.6,Cell line enriched,14.0,ASC diff: 2.0
20,LMOD2,,ENSG00000170807,Leiomodin 2,7,123655807-123664290,Predicted intracellular proteins,Evidence at protein level,HPA051039,Enhanced,,,,,Group enriched,Group enriched,19,heart muscle: 506.5;skeletal muscle: 316.7,esophagus: 21.9,Cell line enriched,8.0,HSkMC: 1.0
21,MYOM2,,ENSG00000036448,Myomesin 2,8,2045040-2165552,Predicted intracellular proteins,Evidence at protein level,"HPA001765, HPA005953",Enhanced,,Approved,Mitochondria,,Mixed,Group enriched,19,heart muscle: 197.4;skeletal muscle: 110.2,breast: 8.1,Group enriched,8.0,HEK93: 4.8;SCLC-21H: 2.6;U-266/84: 2.0
22,PPP1R3A,"GM, PPP1R3",ENSG00000154415,Protein phosphatase 1 regulatory subunit 3A,7,113876777-114075920,"Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,,,,,,,Not detected,Group enriched,18,heart muscle: 26.6;skeletal muscle: 53.1,prostate: 2.2,Cell line enriched,59.0,THP-1: 9.8
23,TCAP,"CMD1N, LGMD2G, T-cap, TELE, telethonin",ENSG00000173991,Titin-cap,17,39664187-39666555,"Disease related genes, Predicted intracellular proteins",Evidence at protein level,"CAB004591, HPA026477",Enhanced,,,,Urothelial cancer:4.55e-4 (favourable),Group enriched,Group enriched,18,heart muscle: 2132.6;skeletal muscle: 4963.5,esophagus: 195.0,Cell line enhanced,,SK-BR-3: 5.6
24,LMOD3,,ENSG00000163380,Leiomodin 3,3,69106872-69123032,"Disease related genes, Predicted intracellular proteins",Evidence at protein level,HPA036034,Uncertain,,,,,Tissue enriched,Group enriched,17,heart muscle: 73.7;skeletal muscle: 162.2,esophagus: 6.9,Cell line enhanced,,HSkMC: 2.1
25,NRAP,,ENSG00000197893,Nebulin related anchoring protein,10,113588716-113664127,"Plasma proteins, Predicted intracellular proteins",Evidence at protein level,"HPA037953, HPA037954",Approved,,,,,Group enriched,Group enriched,17,heart muscle: 210.6;skeletal muscle: 814.0,prostate: 30.3,Not detected,,
26,SRL,,ENSG00000185739,Sarcalumenin,16,4189374-4242080,"Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,"HPA041535, HPA045520",Enhanced,,,,,Group enriched,Group enriched,17,heart muscle: 161.0;skeletal muscle: 178.8,esophagus: 10.2,Cell line enriched,11.0,HSkMC: 2.9
27,DHRS7C,SDR32C2,ENSG00000184544,Dehydrogenase/reductase 7C,17,9771434-9791297,"Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,,,,,,,Not detected,Group enriched,16,heart muscle: 62.4;skeletal muscle: 122.7,esophagus: 5.9,Not detected,,
28,TNNC1,TNNC,ENSG00000114854,"Troponin C1, slow skeletal and cardiac type",3,52451102-52454070,"Disease related genes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,"CAB002450, HPA044848, HPA056897",Enhanced,,Approved,Nucleoplasm<br>Actin filaments<br>Mitochondria,,Mixed,Group enriched,16,heart muscle: 4938.6;skeletal muscle: 7104.7,esophagus: 383.0,Cell line enhanced,,CACO-2: 53.1;EFO-21: 58.5;HSkMC: 46.0;U-2 OS: 99.1
29,TRIM63,"IRF, MURF-1, RNF28, SMRZ",ENSG00000158022,Tripartite motif containing 63,1,26051304-26068436,"Enzymes, Predicted intracellular proteins",Evidence at protein level,,,,,,,Tissue enriched,Group enriched,16,heart muscle: 101.2;skeletal muscle: 139.3,esophagus: 7.6,Group enriched,35.0,ASC diff: 11.0;SK-MEL-30: 42.2
30,DUSP27,,ENSG00000198842,Dual specificity phosphatase 27 (putative),1,167094045-167129165,Predicted intracellular proteins,Evidence at protein level,"HPA012608, HPA012912",Uncertain,,Approved,Nucleoplasm,,Group enriched,Group enriched,15,heart muscle: 41.9;skeletal muscle: 39.7,"placenta,prostate: 2.6",Cell line enriched,11.0,RH-30: 13.7
31,FITM1,FIT1,ENSG00000139914,Fat storage inducing transmembrane protein 1,14,24131275-24132849,Predicted membrane proteins,Evidence at protein level,HPA019842,Uncertain,,,,Liver cancer:1.00e-3 (favourable),Mixed,Group enriched,15,heart muscle: 45.8;skeletal muscle: 113.0,spleen: 5.4,Cell line enriched,23.0,RH-30: 60.8
32,HFE2,"haemojuvelin, hemojuvelin, HFE2A, HJV, JH, RGMC",ENSG00000168509,Hemochromatosis type 2 (juvenile),1,146017468-146036746,"Disease related genes, Predicted membrane proteins, Predicted secreted proteins",Evidence at protein level,,,,,,,Tissue enriched,Group enriched,15,heart muscle: 45.4;liver: 123.4;skeletal muscle: 212.6,esophagus: 8.6,Cell line enhanced,,HSkMC: 1.1;K-562: 1.4
33,KLHL38,C8ORFK36,ENSG00000175946,Kelch like family member 38,8,123645527-123652950,Predicted intracellular proteins,Evidence at protein level,"HPA024770, HPA027115",Uncertain,,Uncertain,Nucleoplasm<br>Vesicles,,Tissue enhanced,Group enriched,15,heart muscle: 35.8;skeletal muscle: 91.2,smooth muscle: 4.3,Cell line enhanced,,BJ hTERT+: 1.4;SK-BR-3: 2.1;U-2197: 4.6
34,PERM1,"C1orf170, MGC13275, Perm1, RP11-54O7.8",ENSG00000187642,"PPARGC1 and ESRR induced regulator, muscle 1",1,975204-982093,Predicted intracellular proteins,Evidence at protein level,"HPA031711, HPA031712",Enhanced,,,,Renal cancer:1.95e-4 (unfavourable),Mixed,Group enriched,15,heart muscle: 20.7;skeletal muscle: 68.1,esophagus: 3.0,Cell line enhanced,,HaCaT: 1.3;SK-BR-3: 1.2
35,SMCO1,"C3orf43, DKFZp313B0440, FLJ41923",ENSG00000214097,Single-pass membrane protein with coiled-coil domains 1,3,196506877-196515366,Predicted intracellular proteins,Evidence at transcript level,HPA061937,Uncertain,,,,,Not detected,Group enriched,15,heart muscle: 24.2;skeletal muscle: 51.1,esophagus: 2.5,Not detected,,
36,ADPRHL1,ARH2,ENSG00000153531,ADP-ribosylhydrolase like 1,13,113399610-113453524,Predicted intracellular proteins,Evidence at protein level,HPA066478,Enhanced,,Approved,Nucleoplasm,"Liver cancer:2.55e-5 (unfavourable), Head and neck cancer:4.88e-4 (unfavourable)",Mixed,Group enriched,14,heart muscle: 258.3;skeletal muscle: 114.3,fallopian tube: 13.2,Cell line enhanced,,SCLC-21H: 24.5;T-47d: 35.4
37,ANKRD2,ARPP,ENSG00000165887,Ankyrin repeat domain 2,10,97572499-97583884,Predicted intracellular proteins,Evidence at protein level,"HPA040842, HPA040884",Enhanced,,Enhanced,Vesicles,,Tissue enhanced,Group enriched,14,heart muscle: 35.9;skeletal muscle: 119.4,kidney: 5.6,Cell line enhanced,,A-431: 14.1;HaCaT: 11.0;RPTEC TERT1: 10.3
38,XIRP1,"CMYA1, DKFZp451D042, Xin",ENSG00000168334,Xin actin binding repeat containing 1,3,39183210-39192596,Predicted intracellular proteins,Evidence at protein level,"HPA016750, HPA018458, CAB026391",Enhanced,,Approved,Nucleus<br>Actin filaments,,Tissue enhanced,Group enriched,14,heart muscle: 113.0;skeletal muscle: 58.4,esophagus: 5.9,Cell line enhanced,,HSkMC: 3.2;RH-30: 2.9
39,APOBEC2,"ARCD1, ARP1",ENSG00000124701,Apolipoprotein B mRNA editing enzyme catalytic subunit 2,6,41053304-41064511,"Enzymes, Predicted intracellular proteins",Evidence at protein level,"HPA014252, HPA017957",Enhanced,,,,,Tissue enhanced,Group enriched,13,heart muscle: 120.7;skeletal muscle: 403.8,esophagus: 19.5,Cell line enhanced,,CACO-2: 3.3
40,GPR22,,ENSG00000172209,G protein-coupled receptor 22,7,107470018-107475659,"G-protein coupled receptors, Predicted membrane proteins",Evidence at transcript level,,,,,,,Not detected,Group enriched,13,"adrenal gland: 1.2;cerebral cortex: 4.7;cervix, uterine: 3.2;endometrium: 2.5;heart muscle: 5.4",smooth muscle: 0.2,Cell line enriched,29.0,SH-SY5Y: 2.9
41,LDB3,"CMD1C, KIAA0613, PDLIM6, ZASP",ENSG00000122367,LIM domain binding 3,10,86668449-86736068,"Disease related genes, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,HPA048955,Enhanced,,Supported,Nucleoplasm<br>Focal adhesion sites<br>Cytosol,,Mixed,Group enriched,13,heart muscle: 568.8;skeletal muscle: 1039.8,prostate: 60.3,Cell line enhanced,,HSkMC: 2.3;SCLC-21H: 6.3;SK-MEL-30: 2.1
42,MYOM1,,ENSG00000101605,Myomesin 1,18,3066807-3220108,Predicted intracellular proteins,Evidence at protein level,"HPA014305, HPA049193",Enhanced,,,,,Tissue enhanced,Group enriched,13,heart muscle: 278.1;skeletal muscle: 299.1,gallbladder: 22.9,Group enriched,12.0,HAP1: 13.8;HMC-1: 3.1;HSkMC: 4.5
43,MB,PVALB,ENSG00000198125,Myoglobin,22,35606764-35637951,"Candidate cardiovascular disease genes, Plasma proteins, Predicted intracellular proteins, Transporters",Evidence at protein level,"CAB000060, HPA003123",Enhanced,,,,,Group enriched,Group enriched,12,heart muscle: 6603.8;skeletal muscle: 12284.0,esophagus: 762.7,Cell line enhanced,,SiHa: 20.1;SK-BR-3: 131.2;T-47d: 36.7
44,SYNPO2L,FLJ12921,ENSG00000166317,Synaptopodin 2 like,10,73644881-73663803,"Plasma proteins, Predicted intracellular proteins",Evidence at protein level,"HPA055192, HPA057142",Enhanced,,Approved,Nuclear speckles<br>Cell Junctions<br>Cytosol,,Group enriched,Group enriched,12,heart muscle: 168.4;skeletal muscle: 95.9,esophagus: 11.1,Cell line enhanced,,CACO-2: 3.4;HSkMC: 2.3;RH-30: 3.0;SK-BR-3: 2.5
45,MYH7B,"dJ756N5.1, KIAA1512, MHC14, MYH14",ENSG00000078814,Myosin heavy chain 7B,20,34975403-35002437,Predicted intracellular proteins,Evidence at protein level,,,,,,Urothelial cancer:8.44e-5 (favourable),Mixed,Group enriched,11,heart muscle: 46.9;skeletal muscle: 55.9;testis: 11.7,"cerebral cortex,prostate: 3.3",Cell line enhanced,,U-138 MG: 1.5
46,MYL3,"CMH8, MLC1SB, MLC1V, VLC1",ENSG00000160808,Myosin light chain 3,3,46857872-46882169,"Candidate cardiovascular disease genes, Disease related genes, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,"HPA016564, CAB018662, HPA046859, HPA063034",Enhanced,,Approved,Nucleoli<br>Mitochondria,Renal cancer:1.22e-8 (favourable),Tissue enhanced,Group enriched,11,heart muscle: 1578.0;skeletal muscle: 1730.1,esophagus: 157.4,Cell line enhanced,,CACO-2: 6.4;HSkMC: 5.6;RPTEC TERT1: 27.5
47,HSPB3,HSPL27,ENSG00000169271,Heat shock protein family B (small) member 3,5,54455601-54456384,"Disease related genes, Predicted intracellular proteins",Evidence at protein level,,,,,,,Tissue enriched,Group enriched,10,heart muscle: 212.2;skeletal muscle: 64.3,esophagus: 14.0,Cell line enhanced,,BJ hTERT+: 56.3;fHDF/TERT166: 24.5;HSkMC: 9.6
48,LRRC39,MGC14816,ENSG00000122477,Leucine rich repeat containing 39,1,100148449-100178273,Predicted intracellular proteins,Evidence at protein level,HPA077159,Enhanced,,,,,Mixed,Group enriched,10,heart muscle: 81.3;skeletal muscle: 175.6,testis: 12.3,Cell line enhanced,,SK-MEL-30: 5.8
49,ABRA,STARS,ENSG00000174429,Actin binding Rho activating protein,8,106759483-106770245,Predicted intracellular proteins,Evidence at transcript level,,,,,,,Not detected,Group enriched,9,heart muscle: 11.0;skeletal muscle: 49.8,esophagus: 3.3,Not detected,,
50,KBTBD12,"FLJ46299, KLHDC6",ENSG00000187715,Kelch repeat and BTB domain containing 12,3,127915232-127987671,Predicted intracellular proteins,Evidence at protein level,,,,,,,Mixed,Group enriched,9,heart muscle: 9.2;skeletal muscle: 20.3,stomach: 1.5,Not detected,,
51,KCNIP2,KCHIP2,ENSG00000120049,Potassium voltage-gated channel interacting protein 2,10,101825974-101843920,Predicted intracellular proteins,Evidence at protein level,,,,,,,Mixed,Group enriched,9,adipose tissue: 238.6;cerebral cortex: 81.4;heart muscle: 108.2,breast: 16.6,Cell line enhanced,,HEL: 13.8;HMC-1: 9.2
52,MURC,"cavin-4, CAVIN4",ENSG00000170681,Muscle related coiled-coil protein,9,100578079-100587906,Predicted intracellular proteins,Evidence at protein level,"HPA020973, HPA020987, HPA021021",Enhanced,,Supported,Nucleoplasm<br>Golgi apparatus<br>Plasma membrane,,Tissue enhanced,Group enriched,9,heart muscle: 34.8;skeletal muscle: 103.8,prostate: 7.4,Cell line enhanced,,NTERA-2: 9.6;SCLC-21H: 17.1
53,SCN2B,,ENSG00000149575,Sodium voltage-gated channel beta subunit 2,11,118161951-118176673,"Disease related genes, FDA approved drug targets, Predicted membrane proteins, Transporters",Evidence at protein level,,,,,,,Mixed,Group enriched,9,cerebral cortex: 34.7;heart muscle: 7.1,smooth muscle: 2.4,Cell line enhanced,,U-2197: 1.6
54,SMYD1,"BOP, KMT3D, ZMYND22",ENSG00000115593,SET and MYND domain containing 1,2,88067780-88113387,"Enzymes, Predicted intracellular proteins",Evidence at protein level,HPA062282,Enhanced,,,,,Tissue enhanced,Group enriched,9,heart muscle: 107.0;skeletal muscle: 170.8;smooth muscle: 38.5,parathyroid gland: 11.6,Not detected,,
55,TMEM182,FLJ30294,ENSG00000170417,Transmembrane protein 182,2,102736905-103019900,"Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,HPA045861,Uncertain,,Approved,Nucleoplasm<br>Vesicles,,Expressed in all,Group enriched,9,heart muscle: 56.8;skeletal muscle: 44.4,prostate: 5.8,Mixed,,
56,ASB18,,ENSG00000182177,Ankyrin repeat and SOCS box containing 18,2,236194872-236264409,"Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,HPA068447,Approved,,,,,Not detected,Group enriched,8,heart muscle: 4.3;skeletal muscle: 3.6;testis: 1.0,cerebral cortex: 0.4,Not detected,,
57,CMYA5,"C5orf10, DKFZp451G223, myospryn, SPRYD2, TRIM76",ENSG00000164309,Cardiomyopathy associated 5,5,79689877-79800240,Predicted intracellular proteins,Evidence at protein level,,,,,,,Mixed,Group enriched,8,heart muscle: 102.2;skeletal muscle: 172.4,ovary: 18.2,Cell line enhanced,,RT4: 1.2;THP-1: 3.6
58,CTAG2,"CAMEL, CT6.2a, CT6.2b, ESO2, LAGE-1, LAGE-1a, LAGE-1b, LAGE1, MGC138724, MGC3803",ENSG00000126890,Cancer/testis antigen 2,X,154651972-154653579,"Cancer-related genes, Predicted intracellular proteins",Evidence at protein level,HPA071467,Enhanced,,,,Liver cancer:2.35e-4 (unfavourable),Mixed,Group enriched,8,fallopian tube: 2.6;heart muscle: 3.2;placenta: 3.6;skeletal muscle: 1.2;testis: 6.0,pancreas: 0.4,Group enriched,29.0,K-562: 126.4;RPMI-8226: 215.0;SK-BR-3: 146.5;U-266/84: 251.9
59,MYO18B,BK125H2.1,ENSG00000133454,Myosin XVIIIB,22,25742144-26031041,Predicted intracellular proteins,Evidence at protein level,HPA000953,Uncertain,,Supported,Nucleoplasm<br>Centrosome,,Mixed,Group enriched,8,heart muscle: 47.3;skeletal muscle: 52.5,testis: 5.8,Cell line enhanced,,HDLM-2: 9.7;REH: 13.6;RH-30: 29.4;U-2 OS: 13.9;U-266/70: 7.2
60,PGAM2,PGAM-M,ENSG00000164708,Phosphoglycerate mutase 2,7,44062727-44065587,"Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins",Evidence at protein level,"HPA050314, HPA060173",Enhanced,,Approved,Nucleoplasm<br>Cytosol,,Not detected,Group enriched,8,heart muscle: 521.3;skeletal muscle: 1459.5,testis: 126.6,Cell line enriched,10.0,SCLC-21H: 77.0
61,PXDNL,"FLJ25471, PMR1",ENSG00000147485,Peroxidasin like,8,51319578-51809445,"Enzymes, Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,HPA007919,,,Approved,Nucleoplasm<br>Cytosol,Breast cancer:3.27e-5 (unfavourable),Mixed,Group enriched,8,epididymis: 11.5;heart muscle: 24.1;testis: 9.0,adipose tissue: 1.8,Group enriched,7.0,AF22: 7.6;Daudi: 4.2;SH-SY5Y: 6.5
62,ESRRB,"DFNB35, ERR2, ERRb, ERRbeta, ESRL2, NR3B2",ENSG00000119715,Estrogen related receptor beta,14,76310614-76501841,"Disease related genes, Nuclear receptors, Predicted intracellular proteins, Transcription factors",Evidence at protein level,,,,,,,Mixed,Group enriched,7,heart muscle: 2.3;kidney: 5.2;skeletal muscle: 1.7;stomach: 1.5;testis: 1.4,breast: 0.3,Cell line enhanced,,HMC-1: 1.0;K-562: 3.3;U-266/70: 1.2
63,POPDC3,"bA355M14.1, MGC22671, POP3",ENSG00000132429,Popeye domain containing 3,6,105158280-105179995,"Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,HPA012514,,,Approved,Nucleoli<br>Cytosol,"Head and neck cancer:4.43e-4 (unfavourable), Lung cancer:5.79e-4 (unfavourable)",Mixed,Group enriched,7,cerebral cortex: 8.8;heart muscle: 19.8;skeletal muscle: 41.8;testis: 9.1,epididymis: 2.9,Cell line enhanced,,RH-30: 20.5
64,SPHKAP,SKIP,ENSG00000153820,"SPHK1 interactor, AKAP domain containing",2,227979950-228181645,Predicted intracellular proteins,Evidence at protein level,"HPA042499, HPA048168",Enhanced,,,,,Not detected,Group enriched,7,cerebral cortex: 19.4;heart muscle: 19.0,ovary: 2.7,Cell line enriched,17.0,BJ hTERT+: 37.3
65,ASB11,DKFZp779E2460,ENSG00000165192,Ankyrin repeat and SOCS box containing 11,X,15281697-15315656,"Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,HPA000238,Uncertain,,,,,Tissue enriched,Group enriched,6,heart muscle: 30.6;skeletal muscle: 42.1,stomach: 5.8,Not detected,,
66,CAV3,"LGMD1C, LQT9, VIP-21, VIP21",ENSG00000182533,Caveolin 3,3,8733800-8841808,"Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters",Evidence at protein level,"CAB017518, CAB018557, HPA054488",Enhanced,,Supported,Vesicles<br>Plasma membrane,,Tissue enhanced,Group enriched,6,heart muscle: 14.0;skeletal muscle: 63.3,esophagus: 6.0,Group enriched,15.0,LHCN-M2: 19.0;RH-30: 91.1
67,CFAP61,"C20orf26, CaM-IP3, dJ1002M8.3, DKFZP434K156",ENSG00000089101,Cilia and flagella associated protein 61,20,20052514-20360702,"Predicted intracellular proteins, Predicted membrane proteins",Evidence at transcript level,HPA009079,Uncertain,,,,,Mixed,Group enriched,6,fallopian tube: 20.3;heart muscle: 8.5;testis: 29.5,skeletal muscle: 3.3,Cell line enhanced,,HMC-1: 2.1;SCLC-21H: 6.6;U-87 MG: 4.1
68,COX7A1,"COX7A, COX7AH",ENSG00000161281,Cytochrome c oxidase subunit 7A1,19,36150922-36152869,"Predicted intracellular proteins, Predicted membrane proteins, Transporters",Evidence at protein level,,,,,,,Expressed in all,Group enriched,6,heart muscle: 357.0;skeletal muscle: 1077.7,adipose tissue: 117.8,Cell line enhanced,,ASC diff: 34.1;ASC TERT1: 25.4;BJ: 29.4;BJ hTERT+: 23.3;fHDF/TERT166: 41.5;HHSteC: 27.7;HSkMC: 24.9
69,CRYM,DFNA40,ENSG00000103316,Crystallin mu,16,21238874-21303083,"Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins",Evidence at protein level,"HPA019086, HPA030619",Enhanced,,Supported,Cytosol,,Tissue enhanced,Group enriched,6,cerebral cortex: 51.1;heart muscle: 47.8;kidney: 28.4;prostate: 24.7;urinary bladder: 14.8,lung: 5.7,Cell line enhanced,,HEL: 9.4;RPTEC TERT1: 32.9;U-87 MG: 8.7
70,EEF1A2,"EEF1AL, HS1, STN, STNL",ENSG00000101210,Eukaryotic translation elongation factor 1 alpha 2,20,63488013-63499315,"Disease related genes, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,"CAB034019, HPA051759, HPA053862, HPA056990",Approved,,Enhanced,Nucleoli<br>Cytosol,"Endometrial cancer:2.90e-5 (unfavourable), Head and neck cancer:9.11e-4 (unfavourable)",Expressed in all,Group enriched,6,cerebral cortex: 409.3;heart muscle: 425.6;skeletal muscle: 1372.7,adrenal gland: 127.7,Cell line enhanced,,MCF7: 899.8;SCLC-21H: 694.7;T-47d: 410.5;U-2 OS: 431.5
71,HCN4,,ENSG00000138622,Hyperpolarization activated cyclic nucleotide gated potassium channel 4,15,73319859-73369264,"Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters, Voltage-gated ion channels",Evidence at protein level,,,,,,,Group enriched,Group enriched,6,cerebral cortex: 1.4;heart muscle: 1.5;testis: 6.7,adrenal gland: 0.5,Cell line enhanced,,AF22: 1.2;CACO-2: 1.3;NTERA-2: 4.7;U-2 OS: 2.1
72,PGPEP1L,,ENSG00000183571,Pyroglutamyl-peptidase I-like,15,98968230-99007795,"Enzymes, Predicted intracellular proteins",Evidence at transcript level,HPA041781,Uncertain,,,,,Not detected,Group enriched,6,heart muscle: 2.4;skeletal muscle: 10.5;testis: 3.8,"breast,esophagus: 0.9",Cell line enhanced,,U-2 OS: 1.1
73,PRSS42,TESSP2,ENSG00000178055,"Protease, serine 42",3,46829542-46834095,"Enzymes, Predicted secreted proteins",Evidence at transcript level,HPA046925,Uncertain,,,,,Not detected,Group enriched,6,epididymis: 4.8;heart muscle: 8.8;parathyroid gland: 3.1;skeletal muscle: 8.4;testis: 2.0;thyroid gland: 1.9,"breast,cervix, uterine,prostate,seminal vesicle: 0.7",Cell line enhanced,,NTERA-2: 1.0
74,PTP4A3,"PRL-3, PRL-R, PRL3",ENSG00000184489,"Protein tyrosine phosphatase type IVA, member 3",8,141391993-141432454,"Enzymes, Predicted intracellular proteins",Evidence at protein level,HPA003281,Uncertain,,,,Renal cancer:1.81e-5 (unfavourable),Expressed in all,Group enriched,6,heart muscle: 69.6;skeletal muscle: 153.1,prostate: 19.1,Cell line enhanced,,HDLM-2: 232.0;Karpas-707: 52.7;RPMI-8226: 54.1;U-266/84: 59.5
75,SH3BGR,21-GARP,ENSG00000185437,SH3 domain binding glutamate rich protein,21,39445855-39515506,Predicted intracellular proteins,Evidence at protein level,"CAB003685, HPA030690",Enhanced,,Approved,Plasma membrane<br>Cytosol,,Expressed in all,Group enriched,6,heart muscle: 100.8;skeletal muscle: 435.9,prostate: 41.4,Cell line enhanced,,U-87 MG: 100.6
76,SLC4A3,"AE3, SLC2C",ENSG00000114923,Solute carrier family 4 member 3,2,219627327-219641980,"Predicted intracellular proteins, Predicted membrane proteins, Transporters",Evidence at protein level,HPA063498,,,Approved,Nucleoplasm,Urothelial cancer:4.12e-4 (unfavourable),Expressed in all,Group enriched,6,cerebral cortex: 30.0;heart muscle: 119.1;ovary: 47.7,testis: 10.9,Mixed,,
77,TBX5,HOS,ENSG00000089225,T-box 5,12,114353931-114408442,"Disease related genes, Predicted intracellular proteins, Transcription factors",Evidence at protein level,"HPA008786, HPA064683",Uncertain,,Approved,Nucleoplasm,,Mixed,Group enriched,6,heart muscle: 40.0;lung: 18.0;placenta: 46.8,prostate: 6.2,Cell line enhanced,,BJ: 17.0;BJ hTERT+: 36.2;BJ hTERT+ SV40 Large T+: 9.5;BJ hTERT+ SV40 Large T+ RasG12V: 12.1;HAP1: 18.0
78,THBS4,,ENSG00000113296,Thrombospondin 4,5,79991311-80083287,"Cancer-related genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,"CAB004597, HPA042426",Approved,,Approved,Vesicles,Urothelial cancer:3.33e-4 (unfavourable),Expressed in all,Group enriched,6,adipose tissue: 234.3;heart muscle: 113.6;smooth muscle: 388.9,thyroid gland: 44.6,Cell line enhanced,,AF22: 3.1;SCLC-21H: 2.9;THP-1: 4.7;U-2 OS: 3.0
79,TUBA8,TUBAL2,ENSG00000183785,Tubulin alpha 8,22,18110331-18146554,"Disease related genes, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,"HPA043684, CAB046031, HPA063394",Approved,,Supported,Microtubules,,Not detected,Group enriched,6,cerebral cortex: 28.6;heart muscle: 83.0;skeletal muscle: 121.7;testis: 47.4,thyroid gland: 11.2,Group enriched,5.0,NB-4: 19.8;SCLC-21H: 17.4;TIME: 31.1
80,TXLNB,"C6orf198, dJ522B19.2, DKFZp451A175, MDP77",ENSG00000164440,Taxilin beta,6,139240061-139292139,Predicted intracellular proteins,Evidence at protein level,"HPA030401, HPA030402, HPA030403",Enhanced,,,,,Mixed,Group enriched,6,heart muscle: 52.2;skeletal muscle: 102.3,ovary: 13.7,Cell line enhanced,,Daudi: 3.4;RPMI-8226: 2.5;U-698: 4.7
81,TYRP1,"b-PROTEIN, CAS2, CATB, GP75, OCA3, TRP, TYRP",ENSG00000107165,Tyrosinase related protein 1,9,12685439-12710290,"Disease related genes, Predicted membrane proteins, Predicted secreted proteins",Evidence at protein level,"HPA000937, CAB002520",Enhanced,,Supported,Vesicles,,Tissue enriched,Group enriched,6,heart muscle: 40.2;skin: 169.1,kidney: 17.0,Cell line enriched,51.0,SK-MEL-30: 1084.9
82,GRM1,"GPRC1A, mGlu1, MGLUR1, PPP1R85",ENSG00000152822,Glutamate metabotropic receptor 1,6,146027646-146437598,"Disease related genes, G-protein coupled receptors, Plasma proteins, Potential drug targets, Predicted membrane proteins, Transporters",Evidence at protein level,HPA015701,Approved,,Approved,Vesicles,,Not detected,Group enriched,5,cerebral cortex: 7.0;heart muscle: 1.7,kidney: 0.8,Not detected,,
83,LRRC2,,ENSG00000163827,Leucine rich repeat containing 2,3,46515423-46580099,Predicted intracellular proteins,Evidence at protein level,"HPA039138, HPA040096",Approved,,,,,Tissue enhanced,Group enriched,5,heart muscle: 30.0;skeletal muscle: 55.9;thyroid gland: 37.0,endometrium: 7.8,Cell line enhanced,,fHDF/TERT166: 5.6;HEL: 3.8;LHCN-M2: 3.4
84,MTUS2,"CAZIP, ICIS, KIAA0774, TIP150",ENSG00000132938,Microtubule associated tumor suppressor candidate 2,13,28820348-29505947,Predicted intracellular proteins,Evidence at protein level,"HPA031473, HPA031474, HPA031475",Enhanced,,Supported,Microtubules<br>Cytokinetic bridge,,Mixed,Group enriched,5,heart muscle: 33.4;ovary: 9.5,cerebral cortex: 4.2,Cell line enhanced,,HaCaT: 11.7;HeLa: 3.7
85,MYOM3,FLJ35961,ENSG00000142661,Myomesin 3,1,24056035-24112175,Predicted intracellular proteins,Evidence at protein level,"HPA028132, HPA029752",Uncertain,,Approved,Vesicles,Renal cancer:4.28e-6 (favourable),Tissue enhanced,Group enriched,5,heart muscle: 69.9;kidney: 31.8;skeletal muscle: 86.5,testis: 12.1,Cell line enhanced,,A549: 4.2;Hep G2: 12.2
86,PLPP7,"C9orf67, FLJ14662, MGC12921, NET39, PPAPDC3",ENSG00000160539,Phospholipid phosphatase 7 (inactive),9,131289694-131309262,"Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,HPA070252,Uncertain,,Approved,Nucleus<br>Vesicles,,Mixed,Group enriched,5,heart muscle: 32.6;skeletal muscle: 72.2,cerebral cortex: 10.1,Cell line enhanced,,AN3-CA: 10.2;ASC diff: 7.8;SCLC-21H: 13.4;SH-SY5Y: 9.1
87,S100A1,"S100-alpha, S100A",ENSG00000160678,S100 calcium binding protein A1,1,153627926-153632039,"Cancer-related genes, Plasma proteins, Predicted intracellular proteins, Transporters",Evidence at protein level,"CAB002599, HPA006462",Enhanced,,,,"Endometrial cancer:1.12e-4 (unfavourable), Renal cancer:3.08e-4 (unfavourable)",Group enriched,Group enriched,5,heart muscle: 1882.3;skeletal muscle: 995.9,thyroid gland: 267.2,Cell line enhanced,,EFO-21: 122.7;Hep G2: 207.0;SK-MEL-30: 802.9
88,TCF15,"bHLHa40, EC2, PARAXIS",ENSG00000125878,Transcription factor 15 (basic helix-loop-helix),20,603797-610398,"Predicted intracellular proteins, Transcription factors",Evidence at protein level,"HPA050998, HPA060221",Uncertain,,Supported,Nuclear speckles,Ovarian cancer:3.25e-4 (unfavourable),Mixed,Group enriched,5,adipose tissue: 6.3;heart muscle: 3.4;placenta: 4.8;skeletal muscle: 4.6;testis: 1.3,lung: 0.7,Cell line enhanced,,HEL: 9.5;HMC-1: 14.7
